Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1

Interventions

Trastuzumab 9Paclitaxel 8Capecitabine 8trastuzumab deruxtecan 7Fulvestrant 7pertuzumab 5eribulin 5Gemcitabine 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5Doxorubicin 4Carboplatin 4Ado-Trastuzumab Emtansine 4sacituzumab govitecan 3ribociclib 3Vinorelbine 3Epirubicin 3Docetaxel 3selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2neratinib 2larotrectinib 2exemestane 2capivasertib 2abemaciclib 2Letrozole 2Fluorouracil 2Anastrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × exemestane × Breast × Clear all
NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed
478 enrolled 16 charts 1 FDA
Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡